WWW.BOOK.DISLIB.INFO
FREE ELECTRONIC LIBRARY - Books, dissertations, abstract
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 29 | 30 || 32 | 33 |   ...   | 34 |

«2013 Annual Report breakthrough technologies and services focused on Dear Fellow Shareholders, addressing specific customer and market needs. Several ...»

-- [ Page 31 ] --

Note 21: Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 29, 2013.

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2013 and 2012. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.

Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value.

For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

–  –  –

Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices, and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.

Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices at the reporting date.

Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date.

Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities.

Contingent consideration: The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $31.3 million as of December 29, 2013. As of December 29, 2013, the Company has recorded contingent consideration obligations relating to its acquisitions of Dexela Limited, Haoyuan and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $4.9 million. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date, and the remaining weighted average earnout period at December 29, 2013 was two years.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

–  –  –

During the fourth quarter of fiscal year 2012, the Company recorded $74.2 million of pre-tax intangible asset impairment charges related to certain trade names. A description of these impairment charges is included within Note 12. The fair value measurements were determined using a relief from royalty method, which incorporates unobservable inputs, thereby classifying the fair value measurements as a Level 3 measurement within the fair value hierarchy. The primary inputs used in the relief from royalty method, an income-based approach, included estimated prospective cash flows considering the revised useful lives and an estimated royalty rate that would be used by a market participant. The royalty rates ranged from 0.5% to 1.0%, the discount rates ranged from 11.0% to 12.0%, and the useful lives ranged from 1 to 8 years. The identified indefinite-lived intangibles related to the above impairment charges, had a carrying value of $76.4 million and a fair value of $4.5 million as of the impairment date, resulting in an impairment loss of $71.9 million. The identified definitelived intangibles related to the above impairment charges, had a carrying value of $3.8 million and a fair value of $1.5 million as of the impairment date, resulting in an impairment loss of $2.3 million.





The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.

The Company’s senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $397.0 million and $258.0 million as of December 29, 2013 and December 30, 2012, respectively. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2013.

Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.

The Company’s 2015 Notes, with a face value of $150.0 million, had an aggregate carrying value of $150.0 million and a fair value of $165.4 million as of December 30, 2012. The Company’s 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $513.0 million as of December 29, 2013. The 2021 Notes had an NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) aggregate carrying value of $497.2 million, net of $2.8 million of unamortized original issue discount, and a fair value of $558.3 million as of December 30, 2012. The fair value of the 2021 Notes is estimated using market quotes from brokers and are based on current rates offered for similar debt. The Company’s financing lease obligations had an aggregate carrying value of $40.3 million and $34.6 million as of December 29, 2013 and December 30, 2012, respectively, and approximated the fair value as there has been minimal change in the Company’s incremental borrowing rate. As of December 29, 2013, the 2021 Notes and financing lease obligations were classified as Level 2.

As of December 29, 2013, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Note 22: Leases The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2013, 2012, and 2011 amounted to $52.7 million, $60.3 million, and $49.1 million, respectively. Minimum rental commitments under noncancelable operating leases are as follows: $56.5 million in fiscal year 2014, $39.1 million in fiscal year 2015, $27.2 million in fiscal year 2016, $22.5 million in fiscal year 2017, $19.5 million in fiscal year 2018 and $91.5 million in fiscal year 2019 and thereafter.

On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and the Company has deferred $26.5 million of gains which will be amortized in operating expenses over the initial lease term of 15 years. During fiscal year 2013, the Company amortized $0.6 million of deferred gains related to the lease. At December 29, 2013, $25.9 million of these deferred gains remained to be amortized, recorded in long-term liabilities.

Note 23: Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance.

The Company evaluates the performance of its operating segments based on revenue and operating income.

Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1.

The Company realigned its organization at the beginning of fiscal year 2013. The Company’s Informatics business, as well as its field service on products previously sold by the Company’s former Bio-discovery business, were moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2013 reflect this new alignment of the Company’s operating segments. Financial information relating to fiscal years 2012 and 2011 has been retrospectively adjusted to reflect the changes to the

operating segments. The principal products and services of these two operating segments are:

• Human Health. Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.

• Environmental Health. Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.

Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown

in the table below for the fiscal years ended:

–  –  –



Pages:     | 1 |   ...   | 29 | 30 || 32 | 33 |   ...   | 34 |


Similar works:

«Introduction to Herd Production Medicine http://www.vetmed.wsu.edu/courses-jmgay/PMIntroduction.htm Home College of Veterinary Medicine Washington State University WSU Faculty &Staff John Gay, DVM PhD DACVPM AAHP FDIU VCS Introduction to Herd Production Medicine Version 2.4 Updated November 12, 2010 Contents: What is veterinary production medicine? What specialized skills and knowledge are required? What are the basic differences between production and traditional veterinary medicine? How does...»

«Aus der Poliklinik für Zahnerhaltung und Parodontologie der FriedrichAlexander-Universität Erlangen-Nürnberg Klinikdirektor: Prof. Dr. A. Petschelt Dichtigkeitsuntersuchung von adhäsiv eingesetzten Glasfaserstiften Inaugural-Dissertation zur Erlangung der Doktorwürde der Zahnheilkunde an der Medizinischen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg vorgelegt von Matthias Millian aus Schwabach Gedruckt mit Erlaubnis der Medizinischen Fakultät der...»

«© Silgmann Sauna Edelholz | Design precious wood | design Ing. Anton Stöckl, Geschäftsführer | General Manager Relaxation, health and well-being in a natural, harmonious surrounding are the reasons for the inEntspannung, Gesundheit und Wohlbefinden in harmonisch natürlicher Umgebung sind die Gründe für den creasingly growing “wellness trend”. Whether in thermal hotels, on cruise ships or in private surimmer stärker werdenden „Wellnesstrend“. Ob im Thermenhotel, auf...»

«Rheologische in vivo-Untersuchung an der menschlichen Haut mit nicht-invasiven Verfahren DISSERTATION zur Erlangung des Doktorgrades des Fachbereiches Chemie der Universität Hamburg aus dem Institut für Gewerblich Technische Wissenschaften Fachrichtung Körperpflege der Universität Hamburg vorgelegt von Sabine Gütt (geb. Lemke) Hamburg 1998 Die vorliegende Arbeit wurde an der Universität Hamburg in der Zeit von März 1994 bis Dezember 1998 unter der Leitung von Herrn Prof. Dr. M. Rimpler...»

«TECHNISCHE UNIVERSITÄT MÜNCHEN Institut für Medizinische Mikrobiologie, Immunologie und Hygiene (Direktor: Univ.-Prof. Dr. D. Busch) Experimentelle Isolierung und Charakterisierung eines lockwirksamen Stoffes der Süßwasserschnecke Biomphalaria glabrata für den Zwischenwirtsfindungsprozess von Schistosoma mansoni Mirazidien Philip V. Eckardt Vollständiger Abdruck der von der Fakultät für Medizin der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors...»

«Florida Department of Health, Bureau of Epidemiology ESSENCE User Guide Version 1.0 (Oct. 2010) This should be considered an evolving guide due to the periodic changes made to Florida’s ESSENCE system. It will be updated as necessary, and as resources allow. Aaron Kite-Powell, MS Anita Ofori-Addo, MPH Janet Hamilton, MPH Florida Department of Health Division of Disease Control Bureau of Epidemiology 850-245-4444 TABLE OF CONTENTS INTRODUCTION PURPOSE OVERVIEW LIMITATIONS AND OTHER CONTEXT A....»

«Aus der Abteilung für Medizinische Psychologie und Psychotherapie, Medizinische Soziologie und Rehabilitationswissenschaften (Leiter: Prof. Dr. med. Dr. phil. Hermann Faller) am Institut für Klinische Epidemiologie und Biometrie der Universität Würzburg Vorstand: Professor Dr. med. Peter U. Heuschmann Einfluss der Progressiven Muskelrelaxation nach Jacobson auf das psychische Befinden, die Persönlichkeitsdimensionen Extraversion, Introversion und Neurotizismus unter Berücksichtigung von...»

«Living with Asbestos-Related Illness A Self-Care Guide CS107729 Living With Asbestos-Related Illness—A Self-Care Guide Table of Contents –  –  – About this Guide This guide will help you understand the illnesses asbestos may cause and how to take care of yourself if you have any of those conditions. Caregivers may also find the guide useful. Asbestos Exposure and Health Asbestos is a naturally occurring mineral. It is made up of fibers that are so small that you cannot see them....»

«Aus der Klinik für Psychiatrie und Psychotherapie am Campus Charité Mitte der Medizinischen Fakultät Charité – Universitätsmedizin Berlin und der Klinik für Gynäkologie und Geburtsmedizin des Vivantes Humboldt Klinikums Akademisches Lehrkrankenhaus der Medizinischen Fakultät Charité Universitätsmedizin Berlin DISSERTATION Prävalenz von Depressionen und Angststörungen und ihre Einflussfaktoren bei Frauen mit Endometriose zur Erlangung des akademischen Grades Doctor medicinae (Dr....»

«FDA-SOL-1119680 Solicitation Number: FDA-SOL-1119680 Subject: Volumetric Assessment of Wear and Corrosion of Conical Head/Stem Taper Junctions in Explanted Total Hip Replacements to Provide Regulatory Guidance and Better Predict Clinical Success PART 1 – DESCRIPTION This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6, as supplemented with additional information included in this notice. This...»





 
<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.